Arkolith/Insider Trading/NRXP/Form 4

Javitt Jonathan C

Chief Scientist, Director, 10% OwnerNRX Pharmaceuticals, Inc. (NRXP) · full profile →Form 4 · filed Aug 23, 2023
Net Buying
Open-Market Buys
$64K
Open-Market Sells
$0
Net Open-Market Flow
$64K
Transactions
1
1 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 22, 2023Buy(P)200K$0.32$64K346K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-23-094406) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML